Vanda Pharmaceuticals (VNDA) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Vanda Pharmaceuticals (VNDA) over the last 17 years, with Q4 2025 value amounting to $84.9 million.
- Vanda Pharmaceuticals' Cash & Equivalents fell 1706.97% to $84.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $84.9 million, marking a year-over-year decrease of 1706.97%. This contributed to the annual value of $84.9 million for FY2025, which is 1706.97% down from last year.
- According to the latest figures from Q4 2025, Vanda Pharmaceuticals' Cash & Equivalents is $84.9 million, which was down 1706.97% from $70.0 million recorded in Q3 2025.
- In the past 5 years, Vanda Pharmaceuticals' Cash & Equivalents ranged from a high of $354.2 million in Q1 2023 and a low of $49.4 million during Q3 2022
- Moreover, its 5-year median value for Cash & Equivalents was $92.7 million (2024), whereas its average is $107.2 million.
- In the last 5 years, Vanda Pharmaceuticals' Cash & Equivalents soared by 42919.0% in 2023 and then crashed by 6466.17% in 2024.
- Quarter analysis of 5 years shows Vanda Pharmaceuticals' Cash & Equivalents stood at $52.1 million in 2021, then skyrocketed by 159.32% to $135.0 million in 2022, then rose by 0.59% to $135.8 million in 2023, then dropped by 24.67% to $102.3 million in 2024, then fell by 17.07% to $84.9 million in 2025.
- Its Cash & Equivalents was $84.9 million in Q4 2025, compared to $70.0 million in Q3 2025 and $81.0 million in Q2 2025.